Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Projections for the CAGR of the Macular Edema and Macular Degeneration Market Size From 2025 to 2034?
The market size for macular edema and macular degeneration has seen significant expansion in the past few years. Its size is projected to rise from $9.65 billion in 2024 to $10.33 billion in 2025, averaging a compound annual growth rate (CAGR) of 7.0%. Factors driving growth in the historical period include an increase in the elderly population, high rates of diabetes, heightened awareness and early detection, global steps toward improved eye health, advances in pharmaceuticals, and reinforced patient advocacy and support.
The macular edema and macular degeneration market size is expected to see strong growth in the next few years. It will grow to $13.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to personalized medicine approaches, rising awareness in emerging markets, focus on combination therapies, integration with teleophthalmology services, global aging demographics. Major trends in the forecast period include advancements in sustained-release drug delivery, integration of gene therapies, development of novel imaging technologies, personalized treatment approaches based on biomarkers, teleophthalmology for remote monitoring, advancements in artificial intelligence for diagnostics.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13479&type=smp
Which Factors and External Forces Are Driving Demand in the Macular Edema and Macular Degeneration Market?
The growth of the macular edema and macular degeneration market is anticipated to be fueled by an increasing diabetic population. Diabetes, a long-term medical condition, brings high blood sugar levels and can harm the eye’s blood vessels, potentially leading to macular edema and macular degeneration. For example, The National Health Service (NHS England), a public healthcare system in the UK, reported in June 2024 that the count of people identified with pre-diabetes rose to 3,615,330 in 2023, showing an 18% rise from 3,065,825 in 2022. Even more, there was nearly a 25% increase in cases among those under 40, increasing from 173,166 in 2022 to 216,440 in 2023. Thus, the proliferation of the diabetic population is acting as a catalyst for the growth of the macular edema and macular degeneration market.
Which Segments in the Macular Edema and Macular Degeneration Offer the Most Growth?
The macular edema and macular degenerationmarket covered in this report is segmented –
1) By Treatment Type: Drug Therapy; Laser Treatment
2) By Application: Macular Edema; Diabetic Macular Edema (DME); Cystoid Macular Edema (CME); Macular Degeneration; Dry age-related macular degeneration; Wet age-related macular degeneration
3) By End User: Hospitals; Clinics; Other End Users
Subsegments:
1) By Drug Therapy: Anti-VEGF (Vascular Endothelial Growth Factor) Injections; Steroid Injections; Oral Medications; Combination Therapy (Anti-VEGF + Steroids)
2) By Laser Treatment: Focal Laser Photocoagulation; Panretinal Photocoagulation (PRP); Subthreshold Laser Therapy; MicroPulse Laser Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13479&type=smp
What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Macular Edema and Macular Degeneration Market?# Market?
North America was the largest region in the macular edema and macular degeneration market in 2024. The regions covered in the macular edema and macular degeneration market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Cutting-Edge Market Trends Are Expected to Drive theMacular Edema and Macular Degeneration Market’s Growth?
Leading firms in the macular edema and macular degeneration market are striving to enhance their market profitability by creating innovative products such as Vabysmo (faricimab-svoa). This drug is utilized to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). In January 2022, Genentech Inc., a biotech company based in the US, received FDA approval for Vabysmo (faricimab-svoa). It’s a bispecific antibody that functions by targeting the vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), marking it as the first dual-action monoclonal antibody for both conditions. Faricimab has the potential to be a game-changer in the treatment of nAMD and DME, and its approval by the FDA and EU signifies a significant achievement for both Genentech and Roche.
View the full report here:
What Are the Key Elements That Define the Macular Edema and Macular Degeneration Market?
Macular edema and macular degeneration are two different eye conditions that can affect vision. Macular edema is swelling in the part of the retina at the back of the eye, which can cause blurry vision. Macular degeneration is a condition that affects the macula, a part of the retina at the back of the eye that is responsible for central vision. They can be caused by many different conditions, including diabetic retinopathy, retinal vein occlusion, and inflammation, and include age, genetics, smoking, high blood pressure, and obesity.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13479
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model